
KemPharm Submits KP415 NDA to the FDA for the Treatment of ADHD
If approved, KemPharm believes that KP415 may address several unmet needs, including earlier onset of action and longer duration of therapeutic effect vs. other available methylphenidate products CELEBRATION, Fla., March 02, 2020 (GLOBE NEWSWIRE) -- …